N/A
N=2,448
First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Bottom Line
View on ClinicalTrials.gov: NCT00802178 ↗Enrolled (actual)
2,448
Serious AEs
0.0%
Results posted
Nov 2009
Primary outcome: Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boehringer Ingelheim
- Primary completion
- Sep 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated |
403; 323; 73; 15; 19 | — |
| SECONDARY Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I |
-1.20 | — |
| SECONDARY Change From Baseline in UPDRS Part III |
-11.18 | — |
| SECONDARY Global Clinical Assessments of Efficacy of Mirapexin® for All Patients |
1043; 1004; 263; 55; 83 | — |
Summary
In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time
Eligibility Criteria
Inclusion Criteria
- Parkinson Disease patients presenting to neurologist for first time
Exclusion Criteria
- Hypersensitivity to the active substance or to any of the excipients
Data sourced from ClinicalTrials.gov (NCT00802178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.